About Diagnostics Development
The focus of Diagnostics Development is in the research and development of unique reagents and assays for the clinical and research markets. For the introduction and sales of our unique assays to the clinical market, strong alliances are formed with major diagnostics companies.
We also provide services to other companies in their development and analytical and clinical validation of their diagnostic assays.
The company works in close collaboration with Uppsala University.
How it started
The founder of Diagnostics Development was Per Venge. Medical doctor and Professor in Clinical Chemistry at Uppsala University. His research interests is reflected by our products. Per Venge has published about 600 scientific papers in the areas of inflammation and cardiac markers.
Much focus has been on the purification and characterization of a number of novel secretory proteins from the human eosinophil and neutrophil granulocytes some of which are described below.
These achievements were accomplished together with one or several of the numerous PhD-students or post-docs that have been working during the years in the laboratory of Per Venge.
Chymotrypsin-like Cationic Protein (CCP), later renamed Cathepsin G, was the subject of Per Venge´s thesis in 1975
CEACAM8 also known as CD66b was purified from the native source for the first time in 2002
N-acetylglucosamine-6-sulphatase was first purified and described in 2005
Phospholipase B precursor (HPLBII-P) was purified and characterized in 2009. Earlier only known as a hypothetical protein from the human genome sequence
Prolylcarboxypeptidase (PRCP) also known as Angiotensinase C for the first time purified from the native source in 2012